---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-005069"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:32:19.339328+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AlloVir reports $248.1M cash at year-end 2021; JPM presentation ongoing

## Summary
- Unaudited cash, equivalents and marketable securities total $248.1M as of Dec 31, 2021.
- Corporate presentation furnished for J.P. Morgan Healthcare Conference on Jan 10, 2022.
- AlloVir is a leader in allogeneic, off-the-shelf virus-specific T cell therapies.

## SEC filing metadata
- accession: 0001193125-22-005069
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312522005069/0001193125-22-005069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312522005069/d279555d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-005069
- JSON: https://secwatch.observer/filing/0001193125-22-005069.json
- Plain text: https://secwatch.observer/filing/0001193125-22-005069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.